Vivus (VVUS.Q) jumps 47% after FDA approval of improved Pancreaze pancreatic medication

If you’ve had your eye off the biotech sector recently because it doesn’t directly involve gold or cannabis, you’re missing out on one of the better casinos out there. For the high risk, high reward investor, nothing is quite like the thrill of correctly picking when a long, drawn out, US Food and Drug Administration process of approving a new drug finally gets over the line.

Lexagene (LXG.V) positions to revolutionize pathogen detection with breakthrough tech

Food safety is major concern for both producers and distributors, so it’s no surprise that the global food safety testing space is expected to be worth $8.0 billion by 2021. Lexagene (LXG.V) seeks to take commercial pathogen detection to a whole new level with its groundbreaking tech and company President, Daryl Rebeck, explains the how it works and what it could mean for investors. See for yourself. Watch live video from EquityDotGuru on